Raw Roflumilast Powder Pharmaceutical Grade Roflumilast Material Roflumilast

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung-Roflumilast
• Certification: GMP, HSE, ISO 9001, USP, BP
• State: Powder
• Purity: >98%
• Product Name: Roflumilast
• Name: Roflumilast Powder
• Appearance: White Powder
• Color: White Color
• Grade: Phamaceutical Grade
• Assay: HPLC 99%
• Application: Antiasthmatic
• Specific: COA
• Test Method: HPLC UV
• CAS No: 162401-32-3
• Mf: C17h14cl2f2n2o3
• MW: 403.207
• Einecs: 223-583-8
• Dinsity: 1.466
• Melting Point: 158
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Xi′an Shaanxi
• Production Capacity: 5000kg/Month

Product Description

Raw Roflumilast powder Pharmaceutical grade Roflumilast Material Roflumilast

Product Description

Product Datails

Name	Roflumilast
Other Name	Roflumilast powder
CAS No.	162401-32-3
EINECS	223-583-8
MF	C17H14Cl2F2N2O3
MW	403.21

Roflumilast is an oral selective phosphodiesterase 4 (PDE4) inhibitor. It is a benzamide compound and is currently the only phosphatase IV (PDE-4) inhibitor approved for oral treatment of respiratory diseases. Through Chemicalbook, it selectively inhibits PDE4 and blocks the transmission of inflammatory response signals, thereby inhibiting lung tissue damage caused by respiratory diseases such as COPD and asthma. It has been shown to inhibit COPD-related inflammation with a new mode of action.

Application&Function

Roflumilast has antiinflammatory effects and is under development as an orally administered drug for the treatment of
inflammatory conditions of the lungs such as asthma, and chronic obstructive pulmonary disease (COPD).
It is a selective phosphodiesterase 4 (PDE4) (IC50 = 0.8 nM) inhibitor. Inhibition of PDE4 prevents the hydrolysis of
phosphodiesters, which play a key role in signal transduction. This compound has anti-inflammatory properties and is particularly effective at reducing inflammation in lung tissue.
 

Specification